Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.
BeyondSpring Inc (NASDAQ: BYSI) is a clinical-stage biopharmaceutical leader advancing innovative cancer therapies through its Plinabulin pipeline and target protein degradation research. This page serves as the definitive source for verified company updates, providing investors and researchers with essential insights into therapeutic developments and strategic initiatives.
Access timely announcements spanning clinical trial progress, regulatory milestones, and partnership agreements. Our curated collection includes press releases on Plinabulin's multifaceted mechanism of action, updates from global Phase 3 studies, and innovations from the SEED Therapeutics collaboration. Each update is vetted for accuracy to support informed decision-making.
Bookmark this resource for structured access to BeyondSpring's scientific advancements in immuno-oncology and protein degradation technology. Regular updates ensure you maintain current awareness of the company's progress in addressing unmet needs in NSCLC and other oncology indications.
SEED Therapeutics has announced a strategic research collaboration with Eisai Co., to discover and develop novel molecular glue degraders for neurodegeneration and oncology targets. SEED is entitled to receive up to $1.5 billion in upfront and milestone payments, plus tiered royalties. Concurrently, SEED has launched a Series A-3 financing with a first close of $24 million led by Eisai, with a second close targeted for Q4 2024.
The collaboration leverages Eisai's expertise in neurodegeneration and cancer. SEED will lead preclinical discovery activities, while Eisai will have exclusive rights to develop and commercialize resulting compounds. The financing will advance SEED's clinical development of internal programs, including an oral RBM39 Degrader for cancer and a Tau degrader for Alzheimer's disease, as well as expand its TPD platform and pipeline.
BeyondSpring hosted an R&D Day on May 15, 2024, spotlighting their lead asset Plinabulin, which shows promise in treating cancer patients who have failed prior PD-1/PD-L1 inhibitors. Plinabulin has demonstrated significant efficacy in extending overall survival (OS) in phase 3 NSCLC studies and shows potential in combination therapies with chemotherapy or radiation.
SEED Therapeutics, BeyondSpring's subsidiary, focuses on developing molecular glues for undruggable targets using their proprietary TPD platform. SEED plans to file an IND for an oral RBM39 degrader in early 2025 and has a robust pipeline with collaborations, including a partnership with Eli Lilly, which has led to multiple milestone payments.
BeyondSpring Inc. (NASDAQ: BYSI) announced a Research and Development (R&D) Day to discuss Plinabulin's potential as a cancer therapy and updates for SEED Therapeutics. Key Opinion Leaders will present on Plinabulin's immunomodulatory activity and unmet needs post immune-checkpoint-inhibitor failure. SEED Therapeutics updates will also be featured.
BeyondSpring, a biopharmaceutical company, reported positive results for 2023. The company dosed patients in Phase 2 trials for Plinabulin and Keytruda combinations, achieved milestones in molecular glue discovery, and made director appointments. SEED Therapeutics, a subsidiary, reached important pre-clinical milestones. The company's lead drug candidate, Plinabulin, showed promise in various studies, aiming to address unmet medical needs in cancer treatment. Financially, R&D and G&A expenses decreased, resulting in a net loss of $21.0 million for 2023.
BeyondSpring Inc. (NASDAQ: BYSI) has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the SEC, showcasing audited financial statements. The report can be accessed on the SEC's website and the company's site, offering hard copies to shareholders upon request.
FAQ
What is the current stock price of Beyondspring (BYSI)?
What is the market cap of Beyondspring (BYSI)?
